ACC.18

Icosapent Ethyl Significantly Lowers Triglycerides Without Raising LDL-C

By March 14, 2018

The ANCHOR study was not designed to determine effects on hsCRP or CV events.

Suboptimal LDL-C in FH Patient Despite Use of Three Cholesterol-Lowering Meds

By March 13, 2018

Some FH patients may have suboptimal LCL-C despite treatment with PCSK9 inhibitors, statins and ezetimibe.

Canakinumab Does Not Appear to Prevent Diabetes Onset

By March 13, 2018

The new analysis focuses on the remaining 4,960 patients, who had prediabetes at the start of the trial.

Centrifugal-Flow Pump Compared With Axial-Flow Pump in Advanced HF

March 13, 2018

Magnetically levitated centrifugal-flow pump beats mechanical bearing axial-flow pump at two years

Dabigatran Cuts Risk of Major CV Complications in Patients With MINS

By March 13, 2018

The primary efficacy outcome was the combined rate of death from a cardiovascular cause, heart attack, stroke due to inadequate blood supply, blood clots or amputation due to cardiovascular disease.

Novel Inhaled Tx Found to Be Ineffective for Patients With Heart Failure

By March 13, 2018

The trial enrolled 105 patients who had HFpEF causing shortness of breath and fatigue with ordinary or mild physical activity.

Interim Data Show Andexanet Alfa Rapidly Reverses Anti-Factor Xa Activity

By March 13, 2018

ANNEXA-4 is a global, single-arm, open-label clinical trial designed to evaluate andexanet alfa in patients who present with an acute major bleed while receiving apixaban, rivaroxaban, edoxaban or enoxaparin.

Medical Intervention in Barbershops Effective for BP Reduction

By March 12, 2018

The study recruited 319 men at 52 Los Angeles County barbershops.

Alirocumab Tied to Reduced Risk of CV Events, Death in High-Risk Patients

By March 12, 2018

The ODYSSEY Outcomes trial (N=18,924) evaluated the effect of alirocumab on the occurrence of MACE in patients who had an ACS between 1-12 months prior to trial enrollment, and who were already taking maximally-tolerated statins (atorvastatin or rosuvastatin).

Canagliflozin Cuts Hospitalization Risk for HF in Type 2 Diabetes Patients

By March 12, 2018

The results showed canagliflozin was associated with a significant reduction in risk of CV death or HHF by 22%.

Febuxostat Linked to Increased Death Risk in Gout Patients With Heart Disease

March 12, 2018

Participants were followed for a median of 32 months.

Ticagrelor vs Clopidogrel: TIMI Major Bleed Rates Compared Post-Fibrinolysis

By March 12, 2018

After 30 days of treatment the analysis found that major bleeding - the most common complication with blood thinners - occurred at the same level (0.7%) for patients in both treatment groups